Integrated genetic and epigenetic biomarker landscapes in hepatocellular carcinoma: From molecular mechanisms to translational precision oncology

Bibliographic Information
Authors: Aly D.M.; Fteah A.M.; Elrefaiy M.A.; Seddik H.E.
Journal: Gene Reports
Publisher: Elsevier Inc.
Publication Date: 2026
Volume / Issue: Volume 45
Article No.: 102597
ISSN: 24520144
DOI: 10.1016/j.genrep.2026.102597
Scopus: View on Scopus
Document Type: Review
Authors and Affiliations
Aly D.M., Department of Clinical Chemistry, Theodor Bilharz Research Institute, Egypt; Fteah A.M., Department of Clinical Chemistry, Theodor Bilharz Research Institute, Egypt; Elrefaiy M.A., Hepato-gastroenterology Department, Theodor Bilharz Research Institute, Egypt; Seddik H.E., Hepato-gastroenterology Department, Theodor Bilharz Research Institute, Egypt
Abstract
Hepatocellular carcinoma (HCC) remains a formidable global health challenge, characterized by profound molecular heterogeneity and dismal survival rates when diagnosed at advanced stages. Despite extensive discovery of genetic and epigenetic alterations in hepatocellular carcinoma, translation of molecular biomarkers into clinical practice remains limited. This review provides a critical, high-level synthesis of emerging genetic and epigenetic biomarkers in HCC. Mechanistically, we evaluate pivotal somatic alterations, including telomere maintenance (TERT promoter), cell cycle checkpoints (TP53), and Wnt/β-catenin signaling (CTNNB1). We further delineate the functional dimensions of epigenetic dysregulation, focusing on aberrant DNA methylation landscapes, m6 A RNA methylation (m6a) RNA modifications, and non-coding RNA (ncRNA) networks as key regulators of oncogenic signaling, tumor stemness, and immune evasion. Crucially, these molecular axes are appraised through the lens of liquid biopsy paradigms—specifically circulating tumor DNA (ctDNA) and exosomal microRNAs (miRNAs)—highlighting their utility in early surveillance, molecular stratification, and minimal residual disease (MRD) monitoring. Finally, we address the systemic challenges of biomarker implementation in resource-constrained, low- and middle-income countries (LMICs), emphasizing the imperative for assay standardization, cost reduction, and multi-omics synthesis to bridge the gap between experimental molecular oncology and real-world clinical practice. This review proposes a translational classification framework to prioritize HCC biomarkers according to clinical utility, validation status, and implementation feasibility. © 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Keywords
Biomarkers; Epigenetics; Hepatocellular carcinoma; Liquid biopsy; Low- and middle-income countries; Precision oncology; biological marker; circulating tumor DNA; microRNA; data mining; DNA methylation; epigenetic modification; epigenetic RNA modification; human; immune evasion; liver cell carcinoma; minimal residual disease; multiomics; neoplastic cell transformation; personalized cancer therapy; promoter region; review; RNA methylation; signal transduction; survival rate; telomere homeostasis
Citation Information
Scopus Citations: 0
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
